Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The aqueous fraction of Dryopteris ramosa is a botanical research compound derived from the fronds of the fern species *Dryopteris ramosa* (Hope) C. Chr., which belongs to the Dryopteridaceae family. This extract is primarily investigated for its antimicrobial, gastrointestinal, and antioxidant properties. It contains a complex mixture of bioactive phytochemicals, including iriflophenone-3-C-beta-D glucopyranoside as a key constituent, alongside flavonoids, alkaloids, saponins, tannins, glycosides, and triterpenoids. Research has demonstrated its potential efficacy against gastrointestinal pathogens such as *Klebsiella pneumoniae*, *Staphylococcus aureus*, and *Escherichia coli*, as well as its anti-inflammatory and antiulcer activities. Additionally, studies have explored its cytotoxic potential against liver and prostate cancer cell lines. It is currently studied in academic research settings and has no identified commercial pharmaceutical developer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dryopteris ramosa aqueous fraction.